title: [Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
abstract: OBJECTIVE
  The German Adjuvant Breast Cancer Study Group (GABG) conducts trials of preoperative chemotherapy in patients with primary breast cancer using a combination of doxorubicin and docetaxel (ADoc). -
  
  
  METHODS
  We conducted a parallel-grouped phase IIa-study with 42 patients with a conventionally dosed and a dose-dense ADoc-schedule (4 cycles of Doxorubicin 50 mg/m(2), Docetaxel 75 mg/m(2) i. v. day 1, q day 15 or 22; G-CSF day 3-15 only for the dose-dense schedule) and a randomized phase IIb-study (GEPARDO-Study) with 250 patients with ADoc +/- Tamoxifen. Biological factors were determined immunohistochemically on 197 core biopsies before treatment. A comparison to a sequential AC-Doc regimen including 913 patients has been completed recently. -
  
  
  RESULTS
  ADoc can be applicated on schedule in 93 % of all patients. The dose-dense regimen shows a tendency to more toxicity but also to more efficacy. The rate of complete pathological remissions (pCR) was 9.7 %. No difference was found between chemo- and chemoendocrine treatment. Clinically negative lymphnodes and a negative estrogen receptor status is predictive for a higher pCR-rate. To date no differences in toxicity could be found between ADoc and AC-Doc. -
  
  
  CONCLUSIONS
  The dose-dense ADoc regimen is well tolerated and highly effective as preoperative therapy of breast cancer.
authors.affiliation: Universitäts-Frauenklinik Frankfurt am Main. minckwitz@em.uni-frankfurt.de
authors.forename: G
authors.initials: G
authors.lastname: von Minckwitz
authors.forename: G
authors.initials: G
authors.lastname: Raab
authors.forename: M
authors.initials: M
authors.lastname: Schütte
authors.forename: J
authors.initials: J
authors.lastname: Hilfrich
authors.forename: J U
authors.initials: JU
authors.lastname: Blohmer
authors.forename: B
authors.initials: B
authors.lastname: Gerber
authors.forename: S D
authors.initials: SD
authors.lastname: Costa
authors.forename: E
authors.initials: E
authors.lastname: Merkle
authors.forename: H
authors.initials: H
authors.lastname: Eidtmann
authors.forename: D
authors.initials: D
authors.lastname: Lampe
authors.forename: C
authors.initials: C
authors.lastname: Jackisch
authors.forename: A
authors.initials: A
authors.lastname: du Bois
authors.forename: A H
authors.initials: AH
authors.lastname: Tulusan
authors.forename: G
authors.initials: G
authors.lastname: Gademann
authors.forename: H P
authors.initials: HP
authors.lastname: Sinn
authors.forename: A
authors.initials: A
authors.lastname: Caputo
authors.forename: E
authors.initials: E
authors.lastname: Graf
authors.forename: M
authors.initials: M
authors.lastname: Kaufmann
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D002277:Carcinoma / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005858:Germany; D006801:Humans; D015337:Multicenter Studies as Topic; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage; D043823:Taxoids; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D013629:Tamoxifen; D000077143:Docetaxel; D004317:Doxorubicin; D017239:Paclitaxel